Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1967 1
1972 1
1974 1
1975 3
1977 2
1978 1
1979 1
1980 2
1981 7
1982 1
1983 4
1984 5
1985 4
1986 3
1987 4
1988 5
1989 4
1990 12
1991 8
1992 3
1993 13
1994 8
1995 5
1996 9
1997 11
1998 18
1999 14
2000 17
2001 15
2002 11
2003 23
2004 29
2005 31
2006 57
2007 65
2008 67
2009 76
2010 117
2011 162
2012 226
2013 272
2014 326
2015 415
2016 503
2017 830
2018 1009
2019 1153
2020 1697
2021 2103
2022 2605
2023 2669
2024 1057

Text availability

Article attribute

Article type

Publication date

Search Results

14,288 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.
Kang C, Blair HA. Kang C, et al. Drugs. 2022 Jan;82(1):55-62. doi: 10.1007/s40265-021-01650-7. Drugs. 2022. PMID: 34897575 Free PMC article. Review.
In two identical phase III trials in adults with relapsing forms of MS, subcutaneous ofatumumab was more effective than oral teriflunomide in reducing the annualized relapse rate, as well as reducing MRI-detected lesion activity and limiting worsening of disability. …
In two identical phase III trials in adults with relapsing forms of MS, subcutaneous ofatumumab was more effective than oral teriflunomide i …
Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, Barrington W, Kuller LH, Simon MS, Lane D, Johnson KC, Rohan TE, Gass MLS, Cauley JA, Paskett ED, Sattari M, Prentice RL. Chlebowski RT, et al. JAMA. 2020 Jul 28;324(4):369-380. doi: 10.1001/jama.2020.9482. JAMA. 2020. PMID: 32721007 Free PMC article. Clinical Trial.
CEE alone compared with placebo among 10 739 women with a prior hysterectomy was associated with statistically significantly lower breast cancer incidence with 238 cases (annualized rate, 0.30%) vs 296 cases (annualized rate, 0.37%; hazard ratio [HR], …
CEE alone compared with placebo among 10 739 women with a prior hysterectomy was associated with statistically significantly lower breast ca …
Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.
Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, Imperatore G, Linder B, Marcovina S, Pettitt DJ, Pihoker C, Saydah S, Wagenknecht L; SEARCH for Diabetes in Youth Study. Mayer-Davis EJ, et al. N Engl J Med. 2017 Apr 13;376(15):1419-1429. doi: 10.1056/NEJMoa1610187. N Engl J Med. 2017. PMID: 28402773 Free PMC article.
In adjusted pairwise comparisons, the annual rate of increase was greater among Hispanics than among non-Hispanic whites (4.2% vs. 1.2%, P<0.001). ...Adjusted pairwise comparisons showed that the relative annual increase in the incidence of type 2 diabetes …
In adjusted pairwise comparisons, the annual rate of increase was greater among Hispanics than among non-Hispanic whites (4.2% …
Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996-2016.
Carstensen B, Rønn PF, Jørgensen ME. Carstensen B, et al. BMJ Open Diabetes Res Care. 2020 May;8(1):e001071. doi: 10.1136/bmjdrc-2019-001071. BMJ Open Diabetes Res Care. 2020. PMID: 32475839 Free PMC article. Review.
T2D incidence increased 2.5% per year until 2011, decreased until 2014 and increased after that, similar in all ages. The annual decrease in mortality was 0.3% for T1D and 2.9% for T2D. The mortality rate ratio between T1D and T2D was 1.9 for men and 1.6 for women. …
T2D incidence increased 2.5% per year until 2011, decreased until 2014 and increased after that, similar in all ages. The annual decr …
Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017.
Li X, Cao X, Guo M, Xie M, Liu X. Li X, et al. BMJ. 2020 Feb 19;368:m234. doi: 10.1136/bmj.m234. BMJ. 2020. PMID: 32075787 Free PMC article.
METHODS: Mortality and DALYs from chronic respiratory diseases were estimated from the Global Burden of Disease Study 2017 using DisMod-MR 2.1, a Bayesian meta-regression tool. The estimated annual percentage change of the age standardised mortality rate was calcula …
METHODS: Mortality and DALYs from chronic respiratory diseases were estimated from the Global Burden of Disease Study 2017 using DisMod-MR 2 …
Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis.
Chen C, Zhang E, Zhu C, Wei R, Ma L, Dong X, Li R, Sun F, Zhou Y, Cui Y, Liu Z. Chen C, et al. J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):8-22.e23. doi: 10.1016/j.japh.2022.07.009. Epub 2022 Aug 1. J Am Pharm Assoc (2003). 2023. PMID: 36055929 Review.
Eligible RCTs evaluated approved treatments for RMS as monotherapy and reported at least one of the primary outcome measures of interest. The primary outcome was efficacy (annualized relapse rate and 12-week confirmed disability progression) and safety (serio …
Eligible RCTs evaluated approved treatments for RMS as monotherapy and reported at least one of the primary outcome measures of interest …
Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
Davis M, O Connell T, Johnson S, Cline S, Merikle E, Martenyi F, Simpson K. Davis M, et al. Curr Alzheimer Res. 2018;15(8):777-788. doi: 10.2174/1567205015666180119092427. Curr Alzheimer Res. 2018. PMID: 29357799 Free PMC article.
Progression rates from normal cognition to MCI due to AD ranged from 4% to 10% annually. Severity of cognitive impairment and age both increased the likelihood of institutionalization and death. For a cohort of 100 patients with normal cognition at age 65, a 20% reduction …
Progression rates from normal cognition to MCI due to AD ranged from 4% to 10% annually. Severity of cognitive impairment and age bot …
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Lim H, et al. JAMA. 2017 Apr 4;317(13):1338-1348. doi: 10.1001/jama.2017.2719. JAMA. 2017. PMID: 28362912 Free PMC article.
EXPOSURE: Tumor characteristics. MAIN OUTCOMES AND MEASURES: Annual percent changes in age-adjusted thyroid cancer incidence and incidence-based mortality rates by histologic type and SEER stage for cases diagnosed during 1974-2013. ...CONCLUSIONS AND RELEVANCE: Among pati …
EXPOSURE: Tumor characteristics. MAIN OUTCOMES AND MEASURES: Annual percent changes in age-adjusted thyroid cancer incidence and inci …
Survival, disabilities in activities of daily living, and physical and cognitive functioning among the oldest-old in China: a cohort study.
Zeng Y, Feng Q, Hesketh T, Christensen K, Vaupel JW. Zeng Y, et al. Lancet. 2017 Apr 22;389(10079):1619-1629. doi: 10.1016/S0140-6736(17)30548-2. Epub 2017 Mar 10. Lancet. 2017. PMID: 28285816 Free PMC article.
Three pairs of cohorts aged 80-89 years, 90-99 years, and 100-105 years (in total, 19 528 oldest-old participants) were examined; the two cohorts in each pair were born 10 years apart, with the same age at the time of the assessment in the 1998 and 2008 surveys. Four health outco …
Three pairs of cohorts aged 80-89 years, 90-99 years, and 100-105 years (in total, 19 528 oldest-old participants) were examined; the two co …
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, Katz E. Rensel M, et al. Mult Scler. 2022 May;28(6):925-932. doi: 10.1177/13524585211047223. Epub 2021 Oct 1. Mult Scler. 2022. PMID: 34595983 Free PMC article. Clinical Trial.
RESULTS: Eighteen attacks occurred in 13 participants during inebilizumab treatment (annualized attack rate, 0.052 attacks/person-year). Twelve attacks occurred during the first year of treatment, and two each occurred in years 2-4. ...
RESULTS: Eighteen attacks occurred in 13 participants during inebilizumab treatment (annualized attack rate, 0.052 attacks/per …
14,288 results
You have reached the last available page of results. Please see the User Guide for more information.